Moderator: Robert Bazell
The chief leaders of the three principle industry associations will engage top regulatory leaders to discuss the state of regulatory approval in the US and perceptions about greater flexibility in overseas markets.
John Castellani, Chief Executive Officer, PhRMA
Roy Greenberg, MD, Vascular Surgery, Cleveland Clinic
James Greenwood, Chief Executive Officer, BIO
Stephen Ubl, President, AdvaMed
Omar Ishrak, Chief Executive Officer, Medtronic
At a time when economic challenges and healthcare reform are impacting patients, payers, healthcare providers and device manufacturers alike, it is critical for stakeholders across the treatment continuum to work together to find solutions that improve efficiencies and reduce the cost of healthcare - all while delivering better therapeutic options to patients and their physicians. Mr. Ishrak will explore the significant unmet clinical needs that patients and their physicians face, and will make the case for why technology combined with an increased focus on economic value can revitalize the cardiac franchise.
Watson was built to rival human's ability to answer questions posed in natural language with speed, accuracy and confidence. The system passed its first test on Jeopardy!, beating the show's two greatest champions, but the real test will be in applying the underlying data management and analytics technology across industries like healthcare. Join us to see two of Cleveland Clinic's top cardiovascular clinicians challenge Watson and learn about future implications.
Introduction: David Ferrucci, PhD, Principal Investigator, DeepQA/Watson Project, IBM Research
Challenge Host: David Shepler, Jeopardy Challenge Program Manager, IBM
Marc Gillinov, MD
Steve Nissen, MD
Concurrent sessions will be held to allow a deep dive into cutting edge cardiovascular issues.
- Cardiovascular's Special Regulatory Challenges
Moderator: Howard Holstein, Partner, Hogan Lovells US LLP
A top regulatory consultant will moderate a focused discussion between venture capitalists, a top FDA leader and the head of Cleveland Clinic's clinical trial center on pending regulatory changes and their impact on the cardiovascular regulatory landscape.
Jan Garfinkle, Managing Partner, Arboretum Ventures
Michael Lincoff, MD, Vice Chairman, Cardiovascular Medicine, Cleveland Clinic
Rebecca Robertson, Managing Director, Versant Ventures
William Maisel, MD, Deputy Center Director, Sciences and CDRH Chief Scientist, U.S. Food and Drug Administration
- Regenerative Medicine: Is the Dream Becoming a Reality?
Moderator: Stephen Ellis, MD, Invasive / Interventional Cardiology, Cleveland Clinic
Top Executives of leading edge companies give their unique and upbeat perspectives on how regenerative medicine to treat the cardiovascular disease is a short step away from reality.
Rahul Aras, PhD, Chief Executive Officer, Juventas Therapeutics
Andrea Hunt, MD, Vice President Regenerative Medicine, Baxter Healthcare
Randall Mills, PhD, Chief Executive Officer, Osiris Therapeutics
Gil Van Bokkelen, PhD, Chief Executive Officer, Athersys
- Watson in Everyday Clinical Decision Making
Moderator: Roger Longman
The specifics of how systems like Watson will be put into daily use will be examined by IBM team leaders and two highly IT savvy Cleveland Clinic clinicians.
Basit Chaudhry, MD, PhD, Senior Researcher, Clinical Transformation, Healthcare Analytics, IBM Research
David Ferrucci, PhD
Doug Johnston, MD, Staff Cardiac Surgeon, Cleveland Clinic
William Morris, MD, Associate Staff Hospital Medicine, Cleveland Clinic
- Reimbursement: Innovation's Inner Self
Moderator: Carol Harding, Senior Director, Supply Chain Innovations, Cleveland Clinic
Reimbursement considerations are now core to the devlopment of any new product innovation. This session will examine reimbursement of new cardiovascular technologies from the patient, provider, company and government perspective.
Moderator: Carol Harding, Senior Director Supply Chain Innovations, Cleveland Clinic
Bonnie Handke, RN, Senior Director Reimbursement, Medtronic
Sean Lyden, MD, Vascular Surgery, Cleveland Clinic
Gwen Mayes, Executive Vice President, National Patient Advocate Foundation
- Tour of Cleveland Clinic's Global Cardiovascular Innovation Center (GCIC)
GCIC Provides a state-of-the-art home for medical technology companies in all fields. Designed, built and equipped as one of the fist cardiovascular healthcare focused incubators in the U.S., GCIC delivers 50,000 square feet of prime, brand new space.
The Shorby Club
Moderator: Paul Begala, Political Analyst and Commentator, CNN and Columnist, Newsweek and The Daily Beast
Rarely has medical innovation played such a central role in US elective politics. This bipartisan panel of top former elected officials and strategists will discuss how healthcare innovation will play out in the 2012 election and beyond.
Ray Gilmartin, Harvard Business School
Ezra Klein, Columnist, The Washington Post
Gail Wilensky, PhD, Senior Fellow, Project HOPE
CEO, Direct Flow Medical
Director, Division of Cardiovascular Devices, US FDA
CSO, Cordis Corporation
CEO, The Medicines Company
CEO, St. Jude Medical
Former US Vice President
St. Jude Medical
The Washington Post
CEO, Thoratec Corporation
National Patient Advocate Foundation
Foundation Medical Partners
Hogan Lovells US LLP
CEO, Cleveland Heart Lab
CEO, General Electric
CEO, Edwards Lifesciences
Novartis Venture Funds
Acting Director, Center for Medicare and Medicaid Innovation
President, Abbott Vascular
Chief Science and Health Correspondent, NBC
CEO, Real Points
CEO, C.R. Bard
Immelt likes equations almost as much as I like graphs. For health care, it's "cost = usage x price(inflation)." Implication: To tackle cost, you either need to get usage down, by making people healthier or restricting access, or get prices down, either through price controls or innovation.
The rate of medical innovation in the United States has fallen behind global competitors as manufacturers and investors struggle to work through inefficient regulatory processes, said medical industry and manufacturing leaders speaking at a Cleveland Clinic conference Oct. 3.
It's a gathering of technology, medicine and business that over the years has grown in international stature. Now in its ninth year, the assemblage will include machine matching wits with man and various arms of industry associations and competing businesses appearing -- in some cases, for the first time -- side by side.